Literature DB >> 15126364

Celecoxib can prevent tumor growth and distant metastasis in postoperative setting.

Jong-Lyel Roh1, Myung-Whun Sung, Seok-Woo Park, Dae-Seog Heo, Dong Wook Lee, Kwang Hyun Kim.   

Abstract

Much evidence suggests that an inflammatory condition provides a microenvironment favorable for tumor growth. One of the main components in the healing wound is the induction of cyclooxygenase-2 (COX-2) and prostaglandins, and many solid tumors have been known to overexpress COX-2. The present study investigated the relationship between surgical wounds and tumor growth and the roles of COX-2 and inflammatory reaction in this microenvironment. We created surgical wounds in syngeneic mice for the implantation of SCC VII murine cancer cell line. Accelerated tumor growth and increased angiogenesis by surgical wounds were clearly observed in C3H/HeJ mice with SCC VII tumor. The COX-2 expression of peritumoral tissues and leukocyte infiltration partly explained the accelerated tumor growth, especially in the early phase after surgical wounding. Celecoxib had a significantly suppressive effect on tumor growth, angiogenesis, and metastasis in tumor-implanted mice with surgical wounds. This tumor-suppressive action of celecoxib did not show any noticeable side effects on the late wound healing and on the gastrointestinal tracts. Prophylactic use of the drug can be advocated in many clinical situations, such as residual tumors or contamination of surgical fields by tumor cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15126364     DOI: 10.1158/0008-5472.can-03-3050

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells.

Authors:  Andries Zijlstra; Marco Seandel; Tatyana A Kupriyanova; Juneth J Partridge; Mark A Madsen; Elizabeth A Hahn-Dantona; James P Quigley; Elena I Deryugina
Journal:  Blood       Date:  2005-09-20       Impact factor: 22.113

2.  The shunting of arachidonic acid metabolism to 5-lipoxygenase and cytochrome p450 epoxygenase antagonizes the anti-cancer effect of cyclooxygenase-2 inhibition in head and neck cancer cells.

Authors:  Seok-Woo Park; Dae-Seog Heo; Myung-Whun Sung
Journal:  Cell Oncol (Dordr)       Date:  2011-06-08       Impact factor: 6.730

3.  A positive-margin resection model recreates the postsurgical tumor microenvironment and is a reliable model for adjuvant therapy evaluation.

Authors:  Jarrod D Predina; Brendan Judy; Zvi G Fridlender; Louis A Aliperti; Brian Madajewski; Veena Kapoor; Guanjun Cheng; Jon Quatromoni; Olugbenga Okusanya; Sunil Singhal
Journal:  Cancer Biol Ther       Date:  2012-05-23       Impact factor: 4.742

4.  The expression of cyclooxygenase-2 in cervical cancers and Hela cells was regulated by estrogen/progestogen.

Authors:  Yunguang Li; Demin Pu; Yanli Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2007-08

5.  Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery.

Authors:  Jarrod Predina; Evgeniy Eruslanov; Brendan Judy; Veena Kapoor; Guanjun Cheng; Liang-Chuan Wang; Jing Sun; Edmund K Moon; Zvi Gregorio Fridlender; Steven Albelda; Sunil Singhal
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-27       Impact factor: 11.205

6.  Antitumor and anti-metastatic effects of cyclooxygenase-2 inhibition by celecoxib on human colorectal carcinoma xenografts in nude mouse rectum.

Authors:  Itasu Ninomiya; Noboru Nagai; Katsunobu Oyama; Hironori Hayashi; Hidehiro Tajima; Hirohisa Kitagawa; Sachio Fushida; Takashi Fujimura; Tetsuo Ohta
Journal:  Oncol Rep       Date:  2012-06-26       Impact factor: 3.906

7.  Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo.

Authors:  Peter Pyrko; Nathaniel Soriano; Adel Kardosh; Yen-Ting Liu; Jasim Uddin; Nicos A Petasis; Florence M Hofman; Ching-Shih Chen; Thomas C Chen; Axel H Schönthal
Journal:  Mol Cancer       Date:  2006-05-18       Impact factor: 27.401

8.  COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro.

Authors:  Huan-Ching Chuang; Adel Kardosh; Kevin J Gaffney; Nicos A Petasis; Axel H Schönthal
Journal:  Mol Cancer       Date:  2008-05-16       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.